Provided by Tiger Trade Technology Pte. Ltd.

Prime Medicine, Inc.

3.90
+0.400011.43%
Pre-market: 3.88-0.0200-0.51%05:12 EDT
Volume:11.20M
Turnover:42.67M
Market Cap:703.99M
PE:-3.59
High:4.02
Open:3.36
Low:3.30
Close:3.50
52wk High:6.85
52wk Low:2.67
Shares:180.51M
Float Shares:116.00M
Volume Ratio:2.26
T/O Rate:9.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0853
EPS(LYR):-1.3521
ROE:-373.29%
ROA:-46.52%
PB:17.68
PE(LYR):-2.88

Loading ...

Prime Medicine Wins Arbitration with Beam over AATD Therapy PM647

Reuters
·
Jul 08

Prime Medicine, - Initial Clinical Data for Pm647 Expected in 2027

THOMSON REUTERS
·
Jul 08

Prime Medicine, - Arbitration Tribunal Confirms Prime Medicine's Right to Develop and Commercialize Pm647 in Aatd

THOMSON REUTERS
·
Jul 08

Prime Medicine, - Owes no Monetary Damages to Beam Therapeutics

THOMSON REUTERS
·
Jul 08

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

THOMSON REUTERS
·
Jul 08

Prime Medicine, - to Submit Ind And/or Cta for Pm647 in Q3 2026

THOMSON REUTERS
·
Jul 08

Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine today

TIPRANKS
·
Jul 08

CYTK, PRME, DOCS, WBD, LQDA Trending With Analysts

TIPRANKS
·
Jul 04

HC Wainwright Upgrades Prime Medicine to Buy From Neutral, $8 Price Target

MT Newswires Live
·
Jun 29

Prime Medicine Raised to Buy from Neutral by HC Wainwright & Co.

Dow Jones
·
Jun 29

Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)

TIPRANKS
·
Jun 24

Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Prime Medicine, Inc. (PRME)

TIPRANKS
·
Jun 23

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Pm359 for the Treatment of Chronic Granulomatous Disease (Cgd)

THOMSON REUTERS
·
Jun 22

Prime Medicine, Inc. (PRME) Receives a Hold from Morgan Stanley

TIPRANKS
·
Jun 22

Prime Medicine says New Zealand clears clinical trial application for Wilson disease therapy PM577a

Reuters
·
Jun 18

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for Pm577a in H1069q-Mutated Wilson Disease

THOMSON REUTERS
·
Jun 18

Prime Medicine, - Phase 1/2 Trial Initiation Expected in H2 2026; Initial Data Expected in 2027

THOMSON REUTERS
·
Jun 18

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

Simply Wall St.
·
Jun 18

Prime Medicine shareholders elect Kelly, Schenkein as Class I directors at annual meeting

Reuters
·
Jun 09

Prime Medicine posts corporate deck outlining prime editing pipeline focus on Wilson disease, AATD

Reuters
·
Jun 02